Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027625 · ClinicalTrials.gov registry record · Phase 1
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00027625: Completed Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00027625 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027625, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gefitinib with temozolomide in treating patients who have malignant primary glioma.
Interventions
- DRUG temozolomide
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01-28 |
| Est. Completion | 2005-11-01 |
| Phase | Phase 1 |
What the finished NCT00027625 record still lists
NCT00027625 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00027625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027625 about?
NCT00027625 is a clinical study titled "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy may kill more tumor cel...
What is the current status of trial NCT00027625?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01-28. Estimated completion is 2005-11-01.
What interventions are being tested in trial NCT00027625?
The interventions under investigation include: temozolomide (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00027625?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI